Microalbuminuria, another use for paricalcitol? Our experience in advanced chronic kidney disease
Microalbuminuria, ¿otro uso del paricalcitol? Nuestra experiencia en enfermedad renal crónica avanzada
Read
7281
Timeswas read the article
2277
Total PDF
5004
Total HTML
Share statistics
array:21 [ "pii" => "X201325141200115X" "issn" => "20132514" "doi" => "10.3265/Nefrologia.pre2012.Feb.11378" "estado" => "S300" "fechaPublicacion" => "2012-05-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Nefrologia (English Version). 2012;32:401-2" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 4200 "formatos" => array:3 [ "EPUB" => 326 "HTML" => 3184 "PDF" => 690 ] ] "Traduccion" => array:1 [ "es" => array:17 [ "pii" => "X0211699512001152" "issn" => "02116995" "doi" => "10.3265/Nefrologia.pre2012.Feb.11378" "estado" => "S300" "fechaPublicacion" => "2012-05-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Nefrologia. 2012;32:401-2" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 7077 "formatos" => array:3 [ "EPUB" => 307 "HTML" => 6013 "PDF" => 757 ] ] "es" => array:9 [ "idiomaDefecto" => true "titulo" => "Microalbuminuria, ¿otro uso del paricalcitol? Nuestra experiencia en enfermedad renal crónica avanzada" "tienePdf" => "es" "tieneTextoCompleto" => "es" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "401" "paginaFinal" => "402" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Microalbuminuria, another use for paricalcitol? Our experience in advanced chronic kidney disease" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Raquel Blanco-García, Juan J. Bravo-López, Mercedes Moreiras-Plaza, Walfred Nájera-de la Garza, Cynthia Cossio-Annibar, Laura Beato-Coo, Gloria Rodríguez-Goyanes" "autores" => array:7 [ 0 => array:2 [ "nombre" => "Raquel" "apellidos" => "Blanco-García" ] 1 => array:2 [ "nombre" => "Juan J." "apellidos" => "Bravo-López" ] 2 => array:2 [ "nombre" => "Mercedes" "apellidos" => "Moreiras-Plaza" ] 3 => array:2 [ "nombre" => "Walfred" "apellidos" => "Nájera-de la Garza" ] 4 => array:2 [ "nombre" => "Cynthia" "apellidos" => "Cossio-Annibar" ] 5 => array:2 [ "nombre" => "Laura" "apellidos" => "Beato-Coo" ] 6 => array:2 [ "nombre" => "Gloria" "apellidos" => "Rodríguez-Goyanes" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "X201325141200115X" "doi" => "10.3265/Nefrologia.pre2012.Feb.11378" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X201325141200115X?idApp=UINPBA000064" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699512001152?idApp=UINPBA000064" "url" => "/02116995/0000003200000003/v0_201502091350/X0211699512001152/v0_201502091351/es/main.assets" ] ] "itemSiguiente" => array:17 [ "pii" => "X2013251412001141" "issn" => "20132514" "doi" => "10.3265/Nefrologia.pre2012.Mar.11397" "estado" => "S300" "fechaPublicacion" => "2012-05-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Nefrologia (English Version). 2012;32:402-3" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 4281 "formatos" => array:3 [ "EPUB" => 287 "HTML" => 3291 "PDF" => 703 ] ] "en" => array:10 [ "idiomaDefecto" => true "titulo" => "Monitoring haemodialysis in the Cabueñes Hospital" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "402" "paginaFinal" => "403" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Monitorización en hemodiálisis en el Hospital de Cabueñes" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig1" "etiqueta" => "Tab. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" "figura" => array:1 [ 0 => array:4 [ "imagen" => "11397_16025_30585_en_t1_611397.jpg" "Alto" => 384 "Ancho" => 1440 "Tamanyo" => 182074 ] ] "descripcion" => array:1 [ "en" => "Prevalence during 2011" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Ana Suárez-Laurés, Luis Quiñones-Ortiz, Miguel de la Torre-Fernández, Adolfo Torres-Lacalle, Montse de Pablos-Pablo, Susana Puccini, Ramón Forascepi-Roza" "autores" => array:7 [ 0 => array:2 [ "nombre" => "Ana" "apellidos" => "Suárez-Laurés" ] 1 => array:2 [ "nombre" => "Luis" "apellidos" => "Quiñones-Ortiz" ] 2 => array:2 [ "nombre" => "Miguel" "apellidos" => "de la Torre-Fernández" ] 3 => array:2 [ "nombre" => "Adolfo" "apellidos" => "Torres-Lacalle" ] 4 => array:2 [ "nombre" => "Montse" "apellidos" => "de Pablos-Pablo" ] 5 => array:2 [ "nombre" => "Susana" "apellidos" => "Puccini" ] 6 => array:2 [ "nombre" => "Ramón" "apellidos" => "Forascepi-Roza" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "X0211699512001144" "doi" => "10.3265/Nefrologia.pre2012.Mar.11397" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699512001144?idApp=UINPBA000064" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251412001141?idApp=UINPBA000064" "url" => "/20132514/0000003200000003/v0_201502091613/X2013251412001141/v0_201502091614/en/main.assets" ] "itemAnterior" => array:17 [ "pii" => "X2013251412001168" "issn" => "20132514" "doi" => "10.3265/Nefrologia.pre2012.Mar.11422" "estado" => "S300" "fechaPublicacion" => "2012-05-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Nefrologia (English Version). 2012;32:400-1" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 8331 "formatos" => array:3 [ "EPUB" => 332 "HTML" => 7216 "PDF" => 783 ] ] "en" => array:10 [ "idiomaDefecto" => true "titulo" => "Effects of suspending ACE inhibitors and ARBs in advanced chronic kidney disease" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "400" "paginaFinal" => "401" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Efectos de la suspensión de IECA y ARAII en enfermedad crónica avanzada" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig1" "etiqueta" => "Tab. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" "figura" => array:1 [ 0 => array:4 [ "imagen" => "11422_16025_30821_en_t1_411422.jpg" "Alto" => 489 "Ancho" => 1446 "Tamanyo" => 201916 ] ] "descripcion" => array:1 [ "en" => "Evolution of glomerular filtration rate and proteinuria following suspension of ACE inhibitors and ARBs" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Martha E. Díaz-Domínguez, Milagros Fernández-Lucas, Antonio Gomis-Couto, Gloria Ruiz-Roso, José L. Teruel, Carlos Quereda" "autores" => array:6 [ 0 => array:2 [ "nombre" => "Martha E." "apellidos" => "Díaz-Domínguez" ] 1 => array:2 [ "nombre" => "Milagros" "apellidos" => "Fernández-Lucas" ] 2 => array:2 [ "nombre" => "Antonio" "apellidos" => "Gomis-Couto" ] 3 => array:2 [ "nombre" => "Gloria" "apellidos" => "Ruiz-Roso" ] 4 => array:2 [ "nombre" => "José L." "apellidos" => "Teruel" ] 5 => array:2 [ "nombre" => "Carlos" "apellidos" => "Quereda" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "X0211699512001160" "doi" => "10.3265/Nefrologia.pre2012.Mar.11422" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699512001160?idApp=UINPBA000064" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251412001168?idApp=UINPBA000064" "url" => "/20132514/0000003200000003/v0_201502091613/X2013251412001168/v0_201502091614/en/main.assets" ] "en" => array:10 [ "idiomaDefecto" => true "titulo" => "Microalbuminuria, another use for paricalcitol? Our experience in advanced chronic kidney disease" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "401" "paginaFinal" => "402" ] ] "autores" => array:1 [ 0 => array:3 [ "autoresLista" => "Raquel Blanco-García, Juan J. Bravo-López, Mercedes Moreiras-Plaza, Walfred Nájera-de la Garza, Cynthia Cossio-Annibar, Laura Beato-Coo, Gloria Rodríguez-Goyanes" "autores" => array:7 [ 0 => array:4 [ "nombre" => "Raquel" "apellidos" => "Blanco-García" "email" => array:1 [ 0 => "raquel.blanco.garcia@sergas.es" ] "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "affa" ] ] ] 1 => array:3 [ "nombre" => "Juan J." "apellidos" => "Bravo-López" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "affb" ] ] ] 2 => array:3 [ "nombre" => "Mercedes" "apellidos" => "Moreiras-Plaza" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "affa" ] ] ] 3 => array:3 [ "nombre" => "Walfred" "apellidos" => "Nájera-de la Garza" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "affa" ] ] ] 4 => array:3 [ "nombre" => "Cynthia" "apellidos" => "Cossio-Annibar" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "affa" ] ] ] 5 => array:3 [ "nombre" => "Laura" "apellidos" => "Beato-Coo" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "affa" ] ] ] 6 => array:3 [ "nombre" => "Gloria" "apellidos" => "Rodríguez-Goyanes" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "affa" ] ] ] ] "afiliaciones" => array:2 [ 0 => array:3 [ "entidad" => "Servicio de Nefrología, Hospital Xeral de Vigo, Vigo, Pontevedra, " "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "affa" ] 1 => array:3 [ "entidad" => "Servicio de Nefrología, Hospital Universitario Lucus Agusti, Lugo, " "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "affb" ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Microalbuminuria, ¿otro uso del paricalcitol? Nuestra experiencia en enfermedad renal crónica avanzada" ] ] "textoCompleto" => "<p class="elsevierStylePara"><span class="elsevierStyleBold">To the Editor,</span></p><p class="elsevierStylePara">Albuminuria increases the risk of progression of renal failure (RF), even in advanced stages.<span class="elsevierStyleSup">1</span> Renin-angiotensin-aldosterone system (RAAS) inhibitors are the main tool used for reducing albuminuria and slowing the progression of RF, although this treatment is often insufficient.<span class="elsevierStyleSup">2</span> Recently, paricalcitol has been proven effective in reducing albuminuria in certain patients.<span class="elsevierStyleSup">3</span></p><p class="elsevierStylePara">The aim of our study was to assess the usefulness of paricalcitol to reduce albuminuria in patients with stage 4-5 RF.</p><p class="elsevierStylePara"><span class="elsevierStyleBold">Method:</span> We included all patients referred to the predialysis unit. Patients were administered paricalcitol at an initial mean dose of 1±0.3μg/day orally, adjusted for calcium/phosphorous metabolic parameters. Follow-up continued for at least 6 months, with three visits every 2 months, in which albuminuria, MDRD, and calcium/phosphorous metabolism parameters were registered. Treatment with RAAS inhibitors and hidroferol continued without change. Statistical analysis: we used analysis of variance for comparing the means of quantitative variables, Wilcoxon tests for comparing medians, and chi-square tests to compare percentages.</p><p class="elsevierStylePara"><span class="elsevierStyleBold">Results:</span> Our study included a total of 40 patients, 67% males, with a follow-up period of 135-235 days. Baseline MDRD was 19.5±3ml/min, 97.5% of patients had hypertension, and 35% were diabetic. Mean urine albumin-to-creatinine ratio (UACR) was 1932±1641mg/g. Initial calcium-phosphorous metabolism parameters were: calcium: 8.8±0.5mg/dl; phosphorous: 4.5±0.5mg/dl; intact parathyroid hormone (iPTH): 473±143pg/ml. At the start of the follow-up period, 25% of patients received angiotensin-converting enzyme inhibitors, 42.5% angiotensin receptor blockers, 55% hidroferol, and 12.5% calcitriol. During the follow-up period, we observed a significant decrease in MDRD (19.5±3ml/min vs 17.3±3.4ml/min; <span class="elsevierStyleItalic">P</span>=.003). There was also a decrease in iPTH and an increase in calcium, both significant results (473±143pg/ml vs 197±88pg/ml, and 8.84±0.5mg/dl vs 9±0.4mg/dl; <span class="elsevierStyleItalic">P</span>=.00 and <span class="elsevierStyleItalic">P</span>=.01, respectively). We also observed an increase in phosphorous, although this was not significant (4.5±0.5mg/dl vs 4.8±0.6mg/dl; <span class="elsevierStyleItalic">P</span>=.1). UACR decreased over the course of the study from an initial mean value of 1932±1641mg/g to the final mean value of 1417±1284mg/g, a 27% decrease (<span class="elsevierStyleItalic">P</span>=.1). In the group of patients with higher initial UACR values (>3000mg/g), the decrease was significant (4258±944mg/g vs 2786±1630mg/g; <span class="elsevierStyleItalic">P</span>=.03). We observed an increase in patients with normalised albuminuria and a decrease in those with albuminuria >3000mg/g. UACR was not associated with treatment with RAAS inhibitors, hidroferol, or calcitriol. In no cases was suspension of treatment necessary due to altered calcium/phosphorous metabolism or secondary side effects, although 17% of patients required dosage adjustments.</p><p class="elsevierStylePara">Our study shows that treatment with paricalcitol in this group of patients is associated with a significant decrease in UACR, leading to a higher proportion of patients with normal excretion of albumin, in addition to providing better control of bone metabolism. The effect was greatest and most significant in patients with higher initial albumin excretion levels, which is the group with the highest risk for progression of RF.<span class="elsevierStyleSup">4</span></p><p class="elsevierStylePara">It may be that the small sample in our study was insufficient to demonstrate the antiproteinuric effects of this treatment with a greater level of significance. We may not have observed significant results in the control of renal function deterioration because of this same reason. Although it was not an objective of this study, we should also keep in mind the decreased cardiovascular risk associated with reduced UACR.</p><p class="elsevierStylePara"><span class="elsevierStyleBold">Conclusion:</span> Paricalcitol can be effective in halting proteinuria in patients with stage 4-5 chronic renal failure disease and controlling secondary hyperparathyroidism. Its efficacy in preventing the progression of IR must be verified in future studies.</p><p class="elsevierStylePara"> </p><p class="elsevierStylePara"><span class="elsevierStyleBold">Conflicts of interest</span></p><p class="elsevierStylePara"> </p><p class="elsevierStylePara">The authors affirm that they have no conflicts of interest related to the content of this article.</p>" "pdfFichero" => "P1-E536-S3516-A11378-EN.pdf" "tienePdf" => true "bibliografia" => array:2 [ "titulo" => "Bibliography" "seccion" => array:1 [ 0 => array:1 [ "bibliografiaReferencia" => array:4 [ 0 => array:3 [ "identificador" => "bib1" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "1.\u{A0}Burton C, Harris KP. The role of proteinuria in the progression of chronic renal failure. Am J Kidney Dis 1996;27(6):765-75. <a href="http://www.ncbi.nlm.nih.gov/pubmed/8651239" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 1 => array:3 [ "identificador" => "bib2" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Sarafidis PA, Khosia N, Bakris GL. Antihypertensive therapy in the presence of proteinuria. Am J Kidney Dis 2007;49(1):12-26. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17185142" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 2 => array:3 [ "identificador" => "bib3" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Zeeuw D, Agazwal R, Amdahl M, Audhya P, Coyne D, Tushaz G, et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet 2010;376:1543-51. <a href="http://www.ncbi.nlm.nih.gov/pubmed/21055801" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 3 => array:3 [ "identificador" => "bib4" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Ruggenenti P, Perna A, Ghezardi G, Benini R, Remuzzi G. Chronic proteinuric nephropathies. Outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury. Am J Kidney Dis 2000;35(6):1155-65. <a href="http://www.ncbi.nlm.nih.gov/pubmed/10845831" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/20132514/0000003200000003/v0_201502091613/X201325141200115X/v0_201502091614/en/main.assets" "Apartado" => array:4 [ "identificador" => "35438" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Letters to the Editor - Brief papers about basic research or clinical experiences" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/20132514/0000003200000003/v0_201502091613/X201325141200115X/v0_201502091614/en/P1-E536-S3516-A11378-EN.pdf?idApp=UINPBA000064&text.app=https://revistanefrologia.com/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X201325141200115X?idApp=UINPBA000064" ]
| Year/Month | Html | Total | |
|---|---|---|---|
| 2024 November | 4 | 7 | 11 |
| 2024 October | 30 | 54 | 84 |
| 2024 September | 57 | 26 | 83 |
| 2024 August | 49 | 49 | 98 |
| 2024 July | 38 | 24 | 62 |
| 2024 June | 54 | 40 | 94 |
| 2024 May | 62 | 34 | 96 |
| 2024 April | 55 | 34 | 89 |
| 2024 March | 30 | 25 | 55 |
| 2024 February | 28 | 40 | 68 |
| 2024 January | 30 | 25 | 55 |
| 2023 December | 16 | 19 | 35 |
| 2023 November | 41 | 32 | 73 |
| 2023 October | 44 | 30 | 74 |
| 2023 September | 20 | 32 | 52 |
| 2023 August | 31 | 21 | 52 |
| 2023 July | 24 | 27 | 51 |
| 2023 June | 21 | 20 | 41 |
| 2023 May | 46 | 28 | 74 |
| 2023 April | 18 | 14 | 32 |
| 2023 March | 31 | 16 | 47 |
| 2023 February | 37 | 19 | 56 |
| 2023 January | 35 | 26 | 61 |
| 2022 December | 47 | 28 | 75 |
| 2022 November | 30 | 26 | 56 |
| 2022 October | 25 | 37 | 62 |
| 2022 September | 39 | 31 | 70 |
| 2022 August | 35 | 48 | 83 |
| 2022 July | 26 | 33 | 59 |
| 2022 June | 25 | 26 | 51 |
| 2022 May | 33 | 20 | 53 |
| 2022 April | 29 | 40 | 69 |
| 2022 March | 34 | 35 | 69 |
| 2022 February | 25 | 42 | 67 |
| 2022 January | 30 | 35 | 65 |
| 2021 December | 30 | 44 | 74 |
| 2021 November | 20 | 34 | 54 |
| 2021 October | 23 | 42 | 65 |
| 2021 September | 29 | 36 | 65 |
| 2021 August | 20 | 34 | 54 |
| 2021 July | 32 | 32 | 64 |
| 2021 June | 38 | 18 | 56 |
| 2021 May | 41 | 30 | 71 |
| 2021 April | 63 | 48 | 111 |
| 2021 March | 37 | 40 | 77 |
| 2021 February | 17 | 22 | 39 |
| 2021 January | 35 | 15 | 50 |
| 2020 December | 35 | 22 | 57 |
| 2020 November | 17 | 17 | 34 |
| 2020 October | 18 | 15 | 33 |
| 2020 September | 21 | 4 | 25 |
| 2020 August | 35 | 17 | 52 |
| 2020 July | 15 | 10 | 25 |
| 2020 June | 25 | 12 | 37 |
| 2020 May | 28 | 14 | 42 |
| 2020 April | 26 | 18 | 44 |
| 2020 March | 28 | 14 | 42 |
| 2020 February | 21 | 22 | 43 |
| 2020 January | 35 | 23 | 58 |
| 2019 December | 36 | 25 | 61 |
| 2019 November | 24 | 16 | 40 |
| 2019 October | 11 | 10 | 21 |
| 2019 September | 16 | 21 | 37 |
| 2019 August | 12 | 11 | 23 |
| 2019 July | 13 | 21 | 34 |
| 2019 June | 22 | 14 | 36 |
| 2019 May | 19 | 17 | 36 |
| 2019 April | 29 | 32 | 61 |
| 2019 March | 20 | 17 | 37 |
| 2019 February | 17 | 17 | 34 |
| 2019 January | 27 | 26 | 53 |
| 2018 December | 70 | 33 | 103 |
| 2018 November | 68 | 17 | 85 |
| 2018 October | 64 | 14 | 78 |
| 2018 September | 58 | 14 | 72 |
| 2018 August | 59 | 22 | 81 |
| 2018 July | 35 | 16 | 51 |
| 2018 June | 51 | 14 | 65 |
| 2018 May | 46 | 23 | 69 |
| 2018 April | 62 | 11 | 73 |
| 2018 March | 74 | 7 | 81 |
| 2018 February | 54 | 6 | 60 |
| 2018 January | 60 | 6 | 66 |
| 2017 December | 66 | 14 | 80 |
| 2017 November | 45 | 7 | 52 |
| 2017 October | 38 | 10 | 48 |
| 2017 September | 43 | 11 | 54 |
| 2017 August | 42 | 11 | 53 |
| 2017 July | 40 | 9 | 49 |
| 2017 June | 38 | 33 | 71 |
| 2017 May | 44 | 9 | 53 |
| 2017 April | 29 | 14 | 43 |
| 2017 March | 26 | 43 | 69 |
| 2017 February | 16 | 14 | 30 |
| 2017 January | 20 | 14 | 34 |
| 2016 December | 44 | 11 | 55 |
| 2016 November | 68 | 9 | 77 |
| 2016 October | 61 | 10 | 71 |
| 2016 September | 100 | 5 | 105 |
| 2016 August | 157 | 6 | 163 |
| 2016 July | 184 | 11 | 195 |
| 2016 June | 110 | 0 | 110 |
| 2016 May | 116 | 0 | 116 |
| 2016 April | 88 | 0 | 88 |
| 2016 March | 70 | 0 | 70 |
| 2016 February | 93 | 0 | 93 |
| 2016 January | 95 | 0 | 95 |
| 2015 December | 113 | 0 | 113 |
| 2015 November | 81 | 0 | 81 |
| 2015 October | 89 | 0 | 89 |
| 2015 September | 49 | 0 | 49 |
| 2015 August | 76 | 0 | 76 |
| 2015 July | 66 | 0 | 66 |
| 2015 June | 30 | 0 | 30 |
| 2015 May | 44 | 0 | 44 |
| 2015 April | 8 | 0 | 8 |
Show all
